EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS

Matthias Bütikofer iD, Felix Torres iD, Harindranath Kadavath iD, Nina Gämperli iD, Marie Jose Abi Saad, Daniel Zindel, Nicolas Coudevylle iD, Roland Riek iD, Julien Orts iD

Journal of the American Chemical Society · 2025

DOI: 10.1021/jacs.4c16762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Matthias Bütikofer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 2F 353, Vienna, A-1090, Austria. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Drug Discovery, Nuclear Magnetic Resonance, Biomolecular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung, Swiss Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fragment-based drug discovery has emerged as a powerful approach for developing therapeutics against challenging targets, including the GTPase KRAS. Here, we report an NMR-based screening campaign employing state-of-the-art techniques to evaluate a library of 890 fragments against the oncogenic KRAS G12V mutant bound to GMP-PNP. Further HSQC titration experiments identified hits with low millimolar affinities binding within the SI/SII switch region, which forms the binding interface for the effector proteins. To elucidate the binding modes, we applied NMR molecular replacement (NMR2) structure calculations, bypassing the need for a conventional protein resonance assignment. Traditionally, NMR2 relies on isotope-filtered nuclear Overhauser effect spectroscopy experiments requiring double-labeled [13C,15N]-protein. We introduce a cost-efficient alternative using a relaxation-based filter that eliminates isotope labeling while preserving structural accuracy. Validation against standard isotopically labeled workflows confirmed the equivalence of the derived protein-ligand structures. This approach enabled the determination of 12 NMR2 KRAS-fragment complex structures, providing critical insights into structure-activity relationships to guide ligand optimization. These results demonstrate the streamlined integration of NMR2 into a fragment-based drug discovery pipeline composed of screening, binding characterization, and rapid structural elucidation with or without isotopic labeling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Drug DiscoveryNuclear Magnetic Resonance, BiomolecularHumansModels, MolecularLigands

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanLigands

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 2F 353, Vienna, A-1090, Austria.
  • Institute for Molecular Physical Science, Vladimir Prelog Weg 2, Zürich, 8093, Switzerland.
  • NexMR AG, Wiesenstrasse 10A, Schlieren, 8952, Switzerland.
  • St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States.

ORCID-Profile: Matthias Bütikofer, Felix Torres, Harindranath Kadavath, Nina Gämperli, Nicolas Coudevylle, Roland Riek, Julien Orts

Förderung

  • Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
  • Swiss Cancer Research Foundation

Zitieren

APA

Bütikofer, M., Torres, F., Kadavath, H., Gämperli, N., Abi Saad, M. J., Zindel, D., Coudevylle, N., Riek, R., & Orts, J. (2025). N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.4c16762

Vancouver

Bütikofer M, Torres F, Kadavath H, Gämperli N, Abi Saad MJ, Zindel D, et al. N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS. Journal of the American Chemical Society. 2025. doi:10.1021/jacs.4c16762

BibTeX
@article{Btikofer2025,
  author = {Bütikofer, Matthias and Torres, Felix and Kadavath, Harindranath and Gämperli, Nina and Abi Saad, Marie Jose and Zindel, Daniel and Coudevylle, Nicolas and Riek, Roland and Orts, Julien},
  title = {N MR 2 -Based Drug Discovery Pipeline Presented on the Oncogenic Protein KRAS},
  journal = {Journal of the American Chemical Society},
  year = {2025},
  doi = {10.1021/jacs.4c16762}
}
Kostenlos starten →